van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, Gerrsing G-J, van den Ham HA. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open. 2020 Dec 23;4(4):e417-26. doi: 10.1055/s-0040-1721499
Van Hout B, Hawe E, Cohen AT. Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: results of HOKUSAI-VTE randomized trial analysis. TH Open. 2020 Sep 23;4(3):e245-54. doi: 10.1055/s-0040-1716496
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Skajaa N, Horvath-Puho E, Adelborg K, Prandoni P, Rothman KJ, Sorensen HT. Venous thromboembolism in Denmark: seasonality in occurrence and mortality. TH Open. 2019 Jun 18;3(2):e171-9. doi: 10.1055/s-0039-1692399.
Christiansen S, Christensen S, Pedersen L, Gammelager H, Layton JB, Brookhart MA, Christiansen CF. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. Crit Care. 2017 Dec 28;21(1):326. doi: 10.1186/s13054-017-1903-y
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Hansen MK, Gammelager H, Mikkelsen MM, Hjortdal VE, Layton JB, Johnsen SP, Christiansen CF. Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. Crit Care. 2013 Dec 12;17(6):R292. doi: 10.1186/cc13158
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.